EP0555864A1 - Composition for use in oral cavity - Google Patents

Composition for use in oral cavity Download PDF

Info

Publication number
EP0555864A1
EP0555864A1 EP19930102227 EP93102227A EP0555864A1 EP 0555864 A1 EP0555864 A1 EP 0555864A1 EP 19930102227 EP19930102227 EP 19930102227 EP 93102227 A EP93102227 A EP 93102227A EP 0555864 A1 EP0555864 A1 EP 0555864A1
Authority
EP
Grant status
Application
Patent type
Prior art keywords
group
oral cavity
ion
composition
use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19930102227
Other languages
German (de)
French (fr)
Other versions
EP0555864B1 (en )
Inventor
Kazuhi Oshino
Atsushi Yamagishi
Ryozo Nakai
Yasuteru Eguchi
Tetsuji Iwasaki
Yuichi Hioki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43Guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • A61K8/416Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Abstract

A composition for use in the oral cavity is disclosed. The composition comprises (A) an antibacterial compound represented by the following general formula (1),
Figure imga0001

wherein Am+ is a nitrogen-containing antibacterial cation and the counter anion X⁻ represents a monoalkyl phosphate ion, a monoalkenyl phosphate ion, a monoalkyl phosphonate ion, or a monoalkenyl phosphonate ion having a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms, and m is a valence of the cation A, and (B) a vehicle for use in the oral cavity. It exhibits a remarkablely rapid and continued disinfection effect action against oral cavity bacteria, while providing a good taste. Its disinfection effect is not reduced in the presence of surfactants. In addition, it does not color the tooth.

Description

    BACKGROUND OF THE INVENTION Field of the Invention
  • The present invention relates to a composition for use in the oral cavity, which can disinfect bacteria in the oral cavity, has a reduced bitter or astringent taste, and is useful for the prevention or treatment of oral diseases such as dental caries, periodontosis, and the like.
  • Description of Background Art
  • Dental caries and periodontosis (e.g., gingivitis, periodontitis), which are typical diseases in the oral cavity are a type of bacterial infection. Dental caries is considered to be caused by Streptococcus mutans, gingivitis by Actinomyces viscosus, and periodontitis by Prophyromonas gingivilis, Capnocytophaga ochracea, and the like.
  • Accordingly, compositions for oral cavity comprising an antibacterial agent for these bacteria had been developed for the prevention of dental caries and periodontosis, which are commercially available. Examples of such compositions include dentifrices, mouthwashes, and the like, in which a cationic antibacterial compound (e.g., chlorhexidine hydrochloride, cetylpyridinium chloride), a nonionic antibacterial compound (e.g., triclosan), or the like, is incorporated.
  • However, many of the conventional cationic antibacterial agents give a bitter and astringent taste when incorporated in an amount effective for the disinfection. For example, Yamazaki, et al reports that a gargle comprising 0.04% by weight of benzalkonium chloride is not suitable for common use, since it provides an extremely bitter and astringent taste, even though its effect is remarkable ["Oral cavity disinfection effect of benzalkonium chloride", Journal of Dental Critics, 554, 227 (1988)]. Furthermore, these cationic antibacterial compounds decrease their disinfection effects in the presence of an anionic surfactant in a mouthwash composition. Therefore, their use in combination with a nonionic surfactant was proposed (e.g., Japanese Patent Laid-open (kokai) Nos. 101417/1984, 101418/1984, 282317/1990, 109315/1991). The proposed compositions, however, not only failed to improve the taste, but also provided insufficient disinfection effects due to the poor immediate antibacterial effect exhibited by conventional nonionic antibacterial compounds. Thus, the compositions had a drawback in that they could not exhibit sufficient antibacterial actions during use.
  • UK Patent No. 1,431,932 discloses a composition for use in the oral cavity for suppressing formation of dental calculus and dental stone, comprising an antibacterial compound which consists of 2 mols of a quaternary ammonium compound and 1 mol of a monoalkyl phosphate. This composition for use in the oral cavity, however, exhibits no prolonged antibacterial effect and does not provide an improved taste. On the other hand, as compositions for use in the oral cavity to which a phosphate type surfactant is added, Japanese Patent Laid-open (kokai) No. 47542/1978 (USP No. 4,152,421) discloses a dentifrice comprising a monoalkyl phosphate as a foaming agent, which the inventors claim does not change taste of foods and beverages; Japanese Patent Laid-open (kohyo) No. 500061/1979 (USP No. 4,366,146) proposes a dentifrice for preventing formation of spots comprising a monoalkyl phosphate as a film forming material; and USP No. 4,036,950 discloses a composition for use in the oral cavity having a pH of above 6 and comprising an abrasive, a cationic antibacterial compound, and a polyoxyethylene-alkylether phosphate. Of these publications, Japanese Patent Laid-open (kokai) No. 47542/1978 and Japanese Patent Laid-open (kohyo) No. 500061/1979 does not mention the combined use of a cationic surfactant and a phosphate, and the composition proposed in USP No. 4,036,950 provides only insufficient improvement in its taste.
  • Japanese Patent Laid-open (kokai) No. 218605/1990 describes a composition comprising a quaternary ammonium compound and a salt of phosphoric ester and effective as an antibacterial and antiseptic agent for use in the skin or the hair. The specification, however, does not suggest at all the possibility of applying the proposed composition to the oral cavity.
  • An object of the present invention is to provide a composition for use in the oral cavity which exhibits an immediate and long-continued antibacterial activity to bacteria in the oral cavity, provides a good taste, and does not reduce its antibacterial activity even when a surfactant as a detergent is added.
  • The inventors of the present invention have undertaken painstaking investigations and found that a composition comprising a specific antibacterial compound and a vehicle for use in the oral cavity provides little bitter or astringent taste, has an excellent antibacterial activity, and exhibits an immediate and long-lasting continued antibacterial effect, even if a surfactant is added. This finding has led to the completion of the present invention.
  • SUMMARY OF THE INVENTION
  • Specifically, the above object is achieved in the present invention by the provision of a composition for use in the oral cavity comprising:
    • (A) an antibacterial compound represented by the following general formula (1),
      Figure imgb0001
      wherein Am+ is a nitrogen-containing antibacterial cation and the counter anion X⁻ represents a monoalkyl phosphate ion, a monoalkenyl phosphate ion, a monoalkyl phosphonate ion, or a monoalkenyl phosphonate ion having a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms, and m is a valence of the cation A, and
    • (B) a vehicle for use in the oral cavity.
      The above object is further achieved in the present invention by the provision of a composition for use in the oral cavity comprising, in addition to said components (A) and (B),
    • (C) a surfactant represented by the following general formula (7),
      Figure imgb0002
      wherein R¹⁰ is a linear or branched alkyl or alkenyl group with 8 to 30 carbon atoms, and Z¹ and Z² may be the same or different and each individually represents a hydrogen atom, an alkali metal, an alkyl ammonium group, an alkyl ammonium group with a substituted hydroxy group, or a basic amino acid group residue.
  • The above object is still further achieved in the present invention by the provision of a composition for use in the oral cavity comprising,
    • (A') an antibacterial compound represented by the following general formula (8),
      Figure imgb0003
      wherein Am+ is a nitrogen-containing antibacterial cation and the counter anion Y⁻ represents a halogen ion or a gluconate ion, and m is a valence of the cation A, and said components (B) and (C), and wherein the molar amount of component (C) is m times or more of that of component (A').
  • Other objects, features and advantages of the invention will hereinafter become more readily apparent from the following description.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Figure 1 is a chart showing the results of the disinfection test of the composition in Example 2.
  • Figure 2 is a graph showing the rate of adsorption of antibacterial compounds in the compositions according to Example 3.
  • DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS
  • Given as examples of antibacterial compounds of said component (A) used in the composition for use in the oral cavity of the present invention are the compounds represented by the following formulas (2) to (4),
    Figure imgb0004

    wherein at least one of R¹, R², or R³ is a linear or branched alkyl or alkenyl group with 8 to 30 carbon atoms, and others are individually a group selected from methyl group, ethyl group, benzyl group, and a group represented by one of the following formulas,
    Figure imgb0005

    -(CH₂CH₂O)n-H (wherein n is an integer of 1 to 15),
    Figure imgb0006

    or
    Figure imgb0007

    R⁴ represents a group -CH₃, -CH₂CH₃, or -CH₂CH₂OH; and the counter anion X⁻ represents a monoalkyl phosphate ion, a monoalkenyl phosphate ion, a monoalkyl phosphonate ion, or monoalkenyl phosphonate ion having a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms.
  • Among compounds of general formula (2), those having a linear or branched alkyl group with 8 to 14 carbon atoms, e.g., 2-ethylhexyl group, decyl group, dodecyl group, or tetradecyl group or benzyl group, for at least one of R¹ and R², and methyl group and/or group for others are preferable.
    Figure imgb0008

    wherein R⁵ is a linear or branched alkyl group with 10 to 20 carbon atoms, X and X⁻ may be the same or different and each individually represents a monoalkyl phosphate ion, a monoalkenyl phosphate ion, a monoalkyl phosphonate ion, or a monoalkenyl phosphonate ion having a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms.
  • Examples of linear or branched alkyl groups with 10 to 20 carbon atoms represented by R⁵ in general formula (3) include decyl group, dodecyl group, tetradecyl group, hexadecyl group, octadecyl group, eicosyl group, and the like.
  • Given as examples of the monoalkyl phosphate ion, monoalkenyl phosphate ion, monoalkyl phosphonate ion, or monoalkenyl phosphonate ion, which are the counter anions represented by X⁻ or X in formulas (1) to (4), are anions of the following formula (5) or (6),
    Figure imgb0009

    wherein R⁶ is a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms and R⁷ is a hydrogen atom, an alkali metal, an alkyl ammonium group, an alkyl ammonium group with a substituted hydroxy group, or a basic amino acid group residue; and
    Figure imgb0010

    wherein R⁸ is a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms and R⁹ is a hydrogen atom, an alkali metal, an alkyl ammonium group, an alkyl ammonium group with a substituted hydroxy group, or a basic amino acid group residue.
  • As R⁶ and R⁸ in the above general formula (5) or (6), an alkyl group with 10 to 20 carbon atoms is preferable, 12 to 16 carbon atoms more preferable, and 14 carbon atoms most preferable. Specific examples of such alkyl groups are lauryl, myristyl, and cetyl groups, and the like. R⁷ and R⁹ are normally hydrogen atoms. Some portion of counter anions may have an alkali metal (e.g., potassium, sodium), an alkyl ammonium group, an alkyl ammonium group with a substituted hydroxy group, or a basic amino acid group residue for R⁷ or R⁹.
  • The amount of the component (A) in the composition for use in the oral cavity of the present invention is 0.001 to 20% by weight (hereinafter % refers to % by weight), and preferably 0.01 to 1%. An amount outside the above range is not desirable, since if it is less than 0.001%, the antibacterial strength is weakened; if greater than 20%, the stability of the formulation is poor.
  • Commonly used vehicles for the oral cavity, such as those used in toothpaste, toothpowder, liquid dentifrice, mouthwash, gargle, mouth rinse, gum massage cream, troches, chewing gum, candies, or the like, can be used as vehicles for component (B) in the composition for use in the oral cavity of the present invention.
  • Such vehicles for the oral cavity which can be used in the composition of the present invention include abrasives, thickening agents, moisturizers, surfactants, perfumes, sweeteners, preservatives, colorants, water, water-soluble fluorine-containing compounds, silicone, and other effective ingredients.
  • Examples of abrasives include hydrogen calcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble sodium metaphosphate, potassium metaphosphate, silicic acid anhydride, silicic acid hydrate, aluminum silicate, zirconium silicate, bentonite, zeolite, aluminum oxide, aluminum hydroxide, resins and mixtures of these. Among these, silicic acid anhydride, calcium carbonate, zeolite, silicic acid hydrate, and aluminum oxide are especially preferable.
  • Examples of thickening agents include sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, arginates, carrageenan, gum arabic, polyvinyl alcohol, gum tragacanth, starch, sodium polyacrylate, and the like.
  • Examples of moisturizers include polyethylene glycol, propylene glycol, sorbitol, glycerine, maltitol, xylitol, and the like. Of these, glycerine, sorbitol, and the like are preferable.
  • The surfactant is used as a foaming agent or a stabilizing agent for an oil-containing material. Various types of surfactants other than phosphates may be used. Examples of preferable surfactants include sodium alkyl sulfate, sodium alkylbenzenesulfonate, sodium N-acylsarcosinate, N-acylglutamates, polyoxyethylene hydrogenated castor oil, polyoxyethylene-polyoxypropylene block copolymers (pluronic type), fatty acid esters of sucrose, alkylglycosides, fatty acid esters of sorbitan, fatty acid esters of polyoxyethylenesorbitan, alkyldimethylamine oxide, carbobetaine, hydroxycarbobetaine, phosphobetaine, hydroxyphosphobetaine, sulfobetaine, hydroxysulfobetaine, and the like. Of these, water-soluble nonionic and amphoteric surfactants such as polyoxyethylene hydrogenated castor oil, polyoxyethylene-polyoxypropylene block copolymers, fatty acid esters of sucrose, alkylglycosides, fatty acid esters of sorbitan, and fatty acid esters of polyoxyethylenesorbitan, are particular preferable.
  • Examples of perfumes include natural perfumes such as spearmint oil, peppermint oil, wintergreen oil, sassafras oil, clove oil, sage oil, eucalyptus oil, mayonara oil, cinnamon oil, thyme oil, lemon oil, orange oil, and the like; as well as synthetic perfumes such as 1-menthol, anethole, carvone, eugenol, thymol, methyl salicylate, and the like. Examples of sweeteners include saccharin, saccharin sodium, stevioside, neohesperidyldihydrocarcone, beruraruchine, p-methoxycinnamic aldehyde, glycyrrhizinates, aspartame (methyl aspartylphenylalanine), and the like. Examples of preservatives include benzoic acid, sodium benzoate, parahydroxybenzoic esters, and the like. Water-soluble fluorine-containing compounds which can be used include sodium fluoride, sodium monofluorophosphate, and the like. Other effective ingredients include chlorophyll compounds, sodium chloride, vitamin C, vitamin E, nicotinic acid esters, allantoinchlorohydroxy aluminum, azulene, lysozyme chloride, hinokitiol, β-glycyrrhetinic acid, dipotassium glycyrrhizinate, protease, materials extracted from herbal medicines, and the like.
  • The amounts of these oral vehicles used in the composition of the present invention vary according to the formulation. In the case of a liquid composition, such as mouthrinse, mouthwash, and gargle, any vehicles among the above-mentioned oral vehicles can be incorporated with the exception of the abrasive and the thickening agent. In principle, it is desirable to incorporate 1 to 30% of the moisturizer, and 50 to 96% of alcohol and water. The ratio of alcohol and water is preferably 1:1 to 200:1, and more preferably 5:1 to 100:1. The amount of alcohol in the composition is preferably 1 to 20%.
  • When the composition is in the form of a paste, such as toothpaste or liquid dentifrice, all of the above-mentioned vehicles can be incorporated. In principle, it is preferable to incorporate 10 to 75% of the abrasive, 0.5 to 5% of the thickening agent, and 10 to 85% of the moisturizer and water. The abrasive is preferably 20 to 75% in the case of a toothpaste, and 10 to 30% in the case of a liquid dentifrice.
  • For a solid composition such as a toothpowder, the solid ingredients among the above-mentioned vehicles for use in the oral cavity can be blended. Basically, it is preferable to incorporate 60 to 99% of the abrasive.
  • It is preferable that the total content of the perfume and the sweetener in the oral vehicle be 0.01 to 5%. The pH of the composition of the present invention is in the range of 5 to 9.5, preferably, in the range of 6 to 8.
  • The component (C) used in the present invention is a surfactant represented by the above general formula (7), wherein R¹⁰ is a linear or branched alkyl or alkenyl group with 8 to 30 carbon atoms, preferably an alkyl group with 10 to 20 carbon atoms, more preferably 12 to 16 carbon atoms, and most preferably 14 carbon atoms. Specific examples include decyl, lauryl, myristyl, and cetyl groups. Z¹ and Z² are preferably a partial neutralized compound having a neutralization degree of 0.8 to 2.0, especially 1.0 to 1.8. Given as specific examples of component (C) are 1 potassium monodecylphosphate, 1.2 sodium monolaurylphosphate, 1.3 potassium monomyristylphosphate, 1.5 triethanolamine monomyristylphosphate, 1 arginine monomyristylphosphate, 1.3 arginine monomyristylphosphate, 1.2 sodium monocetylphosphate, and the like.
  • These components (C), when added to a composition containing components (A) and (B), exhibit an action of further extending the period of time for which the composition maintains the antibacterial activity. Although the amount of component (C) to be incorporated into the composition for the oral cavity of the present invention varies depending on the desired antibacterial activity and the types of cation (Am+), a preferable amount, in terms of molar ratio, is in the range of (Am+)/(C)=1/2 to 1/100, with a more preferable amount being in the range of (Am+)/(C)=1/2 to 1/50. More specifically, in the case of the antibacterial compound of general formula (2), this amount is in the range of (Am+)/(C)=1/2 to 1/100, and preferably (Am+)/(C)=1/2 to 1/50; in the case of the antibacterial compound of general formula (3), it is in the range of (Am+)/(C)=1/2 to 1/20, and preferably (Am+)/(C)=1/2 to 1/10; and in the case of the antibacterial compound of general formula (4), it is in the range of (Am+)/(C)=1/2 to 1/50, and preferably (Am+)/(C)=1/2 to 1/20.
  • In the present invention, the composition for use in the oral cavity can be prepared either by formulating components (A) and (B) or by formulating component (A'), instead of component (A), and the molar ratio of component (A') to component (C) satisfies (A')/(C)≦1/m. In the case of the composition in which components (A') and (C) are formulated, it is considered that these components (A') and (C) react in the composition to form a salt.
  • Given as examples of antibacterial compounds (8) of component (A') are components represented by the following general formulas (9), (10), and (11).
    Figure imgb0011

    wherein counter anions Y⁻ and Y - 1
    Figure imgb0012
    individually represent a halogen ion, Y₂ is a halogen atom or a gluconic acid residue, and R¹, R², R³, R⁴, and R⁵ are the same as defined above.
  • In the ratio of component (A') to component (C) satisfying the range defined above, an excess amount of component (C) extends the period of time for which the composition maintains the antibacterial activity. In the case where component (C) is added in excess, the molar ratio of (Am+)/(C) is preferably (Am+)/(C) =1/2 to 1/100, and more preferably (Am+)/(C)=1/2 to 1/50, although it depends on the types of the antibacterial cation (Am+). More specifically, in the case of the antibacterial compound of general formula (9), this molar ratio is in the range of (Am+)/(C)=1/2 to 1/100, and preferably (Am+)/(C)=1/2 to 1/50; in the case of the antibacterial compound of general formula (10), it is in the range of (Am+)/(C)=1/2 to 1/20, and preferably (Am+)/(C)=1/2 to 1/10; and in the case of the antibacterial compound of general formula (11), it is in the range of (Am+)/(C)=1/2 to 1/50, and preferably (Am+)/(C)=1/2 to 1/20.
  • The compounds represented by the general formula (1) used in the present invention can be prepared according to known methods. For example, among compounds of the general formula (1), said compound (2) can easily be prepared from a commercially available quaternary ammonium salt, which is a compound represented by said general formula (9) with a halogen atom as the counter ion, by converting it into the OH-type quaternary ammonium salt, and neutralizing it by said compound having an anion residue. Said compound (3) can be prepared by a method comprising submitting a commercially available compound (10) to alkaline conditions, desalting it by electrodialysis, and neutralizing the product with said compound having an anion residue. An alkali metal salt, an amine salt, an organic amine salt, or a basic amino acid salt may be included during the neutralization to the extent that the neutralization is not hindered.
  • Preferable formulas of the composition for use in the oral cavity of the present invention include liquid formulas such as mouthwash, mouth rinse, and gargle; paste formulas such as toothpaste, liquid dentifrice, and gum massage cream; and solid formulas such as toothpowder, and troche.
  • Among the above compositions for use in the oral cavity of the present invention, a solid composition such as a toothpowder can normally be formulated by mechanically blending the above-mentioned solid ingredients. A composition in the form of a paste can normally be formulated by mechanically blending the various ingredients with deaeration.
  • In order to disinfect the oral cavity by using the composition for use in the oral cavity of the present invention, the composition is, in principle, preferably applied about 1-3 times per day, about five days a week. Among the forms of the composition, a mouth rinse is the most desirable. Disinfection can be effectively performed using about 10 ml of the mouth rinse of the present invention after brushing, holding in the mouth for about 30 seconds, then ejecting.
  • The composition for use in the oral cavity of the present invention exhibits a remarkablely rapid disinfection effect and continued antibacterial effect action against oral cavity bacteria while providing a good taste. Its disinfection effect is not reduced in the presence of surfactants.
  • Other features of the invention will become apparent in the course of the following description of the exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
  • EXAMPLES
  • The following compounds were used in the Examples.
  • Invention Compound 1
  • Figure imgb0013
  • Invention Compound 2
  • Figure imgb0014
  • Invention Compound 3
  • Figure imgb0015
  • Invention Compound 4
  • Figure imgb0016
  • Invention Compound 5
  • Figure imgb0017
  • Invention Compound 6
  • Figure imgb0018
  • Invention Compound 7
  • Figure imgb0019
  • Invention Compound 8
  • Figure imgb0020
  • Comparative Compound 1
  • Figure imgb0021
  • Comparative Compound 2
  • Figure imgb0022
  • Comparative Compound 3
  • Figure imgb0023
  • Comparative Compound 4
  • Figure imgb0024
  • Comparative Compound 5
  • Figure imgb0025
  • Comparative Compound 6
  • Figure imgb0026
  • Example 1
  • Antibacterial compounds in Table 1 were evaluated in terms of their taste.
  • Evaluation was performed by a panel of 5 adult men and 5 adult women. 20 ml of a 1% ethanol solution containing 0.02% or 0.1% of one of the compounds in Table 1 was held in the mouth for 30 seconds to evaluate the taste while gargling and the aftertaste as one of three grades, O (not bad), D (rather bad), or X (bad). Each compound was graded as one of O, D, or X, to which the average of all panelists is closest. The results are shown in Table 1, which manifestly demonstrates a remarkable improvement in the taste of the composition of the present invention.
    Figure imgb0027
  • Example 2
  • A disinfection test was carried out on the compositions shown in Tables 2 and 3.
  • Bacteria collected from saliva of male adults and bacteria causing diseases in the oral cavity, which are named in Table 2, were used for the test. The antibacterial compounds shown in Tables 2 and 3 were added to the test bacterial suspensions to a concentration of 0.01% in a anaerobic globe box (N₂:CO₂:H₂=80:10:10, manufactured by Hirasawa Co.), followed by the further addition of surfactants shown in Tables 2 and 3 to a concentration of 0.1%. The mixture was stirred for 1 minute at 37°C, suitably diluted with physiological saline, and cultured for 5 days at 37°C in BHI agar medium (goat blood hemin and menadione containing, a product of Difco Co.) to measure the number of living bacteria. The results are shown in Table 2 and Figure 1, which show that the compositions for the oral cavity of the present invention exhibited a remarkablly rapid disinfection effect which is not reduced in the presence of surfactants.
    Figure imgb0028
    Figure imgb0029
  • Example 3
  • Benzalkonium chloride (Sanizole, trade mark, a product of Kao Corp.), chlorhexidine gluconate, and cetylpyridinium chloride were selected as antibacterial compounds. An appropriate amount of arginine laurylphosphate (1.3 neutralization) was added to prepare aqueous solutions of antibacterial compound with a concentration of 0.01%. 1 g of hydroxyapatite powder (a product of Wako Pure Chemical Co.), which is a major component of the tooth was added to 20 ml of each solution. After stirring for 30 seconds, the amount the antibacterial compounds in the supernatant was quantitatively measured to calculate their adsorption to the hydroxyapatite.
  • The results are shown in Figure 2, which demonstrates that the rate of adsorption is promoted by the addition of arginine laurylphosphate. It was further confirmed that especially good results could be obtained by adjusting the equivalent ratio of benzalkonium chloride and arginine laurylphosphate to 1:1 to 1:100, the molar ratio of chlorhexidine gluconate and arginine laurylphosphate to 1:1 to 50:1, and the equivalent ratio of cetylpyridinium chloride and arginine laurylphosphate to 1:1 to 1:20.
  • The above results show that the use of the composition for the oral cavity of the present invention can effectively adsorb antibacterial compound to the tooth surface to continuously exhibit the antibacterial action.
  • Comparative Example 4
  • Water, 1 mM benzalkonium chloride, 0.5 mM myristylphospholylated di(benzarconium) (1 mM as benzarconium), 1 mM chlorhexidine gluconate, 1 mM cetylpyridinium chloride, 0.5 mM myristylphospholylated di(cetylpyridinium), and 1 mM monomyristylphospholylated chlorhexidine were used as comparative compounds, and 1 mM myristylphospholylated benzalkonium, 1 mM dimyristylphospholylated chlorhexidine, and 1 mM myristylphospholylated cetylpyridinium, to which an appropriate amount of arginine myristylphosphate was added (1.5 neutralization) were used as invention compounds.
  • Each sample solution was evaluated in terms of the taste during mouthwash and the aftertaste by adult persons by holding 10 ml of the solution in the mouth for 30 seconds while gargling. The rate of bacterial metabolism suppression was determined by collecting saliva after 30 and 60 minutes and measuring its lactic acid producing capability, which is taken as the standard for the antibacterial activity. For the determination of the lactic acid producing capability 0.4 ml of saliva and 0.1 ml of 10% sucrose were reacted for 5 minutes at 37°C, and the reaction product was filtered and submitted to ion chromatography. The rate of suppression of lactic acid production, as the percentage against the amount of lactic acid produced when the person did not wash mouth, was calculated by deducting the amount of lactic acid produced while unreacted as a blank to determine the lactic acid production. The results are shown in Table 4, which indicates that the comparative compounds had unfavorable tastes and hardly maintained their antibacterial effects, while the compounds of the present invention not only provided good taste, but also was proven to promote their prolonged antibacterial effects by the addition of a specific amount of arginine myristylphosphate. Among the above compounds, those having the molar ratio of (antibacterial cation)/(counter anion) greater than the reciprocal of the cation valency, such as myristylphospholylated di(benzalkonium), myristylphospholylated di(cetylpyridinium), and monomyristylphospholylated chlorhexidine, exhibited both unfavorable tastes and poor effects of the continued antibacterial action. On the other hand, the compounds having the molar ratio of (antibacterial cation)/(counter anion) smaller than the reciprocal of the cation valency, such as myristylphospholylated benzarkonium, myristylphospholylated cetylpyridinium, and dimyristylphospholylated chlorhexidine, exhibited both good tastes and excellent effects of the continued antibacterial action.
    Figure imgb0030
  • Example 5
  • Tooth paste compositions were prepared by blending and deaerating the components shown in Table 5.
    Figure imgb0031
  • Example 6
  • Concentrated mouthwash compositions 7 and 8 were prepared by blending the components shown in Table 6. The composition can be used after diluting to a volume of about 30 fold.
    Figure imgb0032
  • Example 7
  • Troche compositions with formulations shown in Table 7 were prepared by blending the components shown in Table 7 and molding the blend into a disk shape by a tabletting machine.
    Figure imgb0033
  • Example 8
  • An aqueous solution of benzethonium chloride or cetylpyridinium chloride and an aqueous solution of sodium monoalkyl (C₁₂) phosphate (pH 7) were mixed to produce white precipitate. To the mixture were added ethanol and polyoxyethylene (EO=40) hydrogenated castor oil to solubilize the precipitate. Mouthwash compositions 11 and 12 were prepared by adding other components shown in Table 1 and blending the mixture.
    Figure imgb0034
  • Example 9 (Mouthwash)
  • The following oil components and water components were dissolved separately and two solutions were mixed to obtain a transparent mouthwash composition. Preferable use of this composition is holding it in mouth after blushing teeth for about 30 seconds and then ejecting.
    Figure imgb0035
    Figure imgb0036

Claims (10)

  1. A composition for use in the oral cavity comprising:
    (A) an antibacterial compound represented by the following general formula (1),
    Figure imgb0037
    wherein Am+ is a nitrogen-containing antibacterial cation and the counter anion X⁻ represents a monoalkyl phosphate ion, a monoalkenyl phosphate ion, a monoalkyl phosphonate ion, or a monoalkenyl phosphonate ion having a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms, and m is a valence of the cation A, and
    (B) a vehicle for use in the oral cavity.
  2. A composition for use in the oral cavity according to Claim 1, wherein said antibacterial compound (A) is a compound represented by the following formula (2),
    Figure imgb0038
    wherein at least one of R¹, R², or R³ is a linear or branched alkyl or alkenyl group with 8 to 30 carbon atoms, and others are individually a group selected from methyl group, ethyl group, benzyl group, and a group represented by one of the following formulas,
    Figure imgb0039
    -(CH₂CH₂O)n-H (wherein n is an integer of 1 to 15),
    Figure imgb0040
    or
    Figure imgb0041
    R⁴ represents a group -CH₃, -CH₂CH₃, or -CH₂CH₂OH; and the counter anion X⁻ represents a monoalkyl phosphate ion, a monoalkenyl phosphate ion, a monoalkyl phosphonate ion, or a monoalkenyl phosphonate ion having a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms.
  3. A composition for use in the oral cavity according to Claim 1, wherein said antibacterial compound (A) is a compound represented by the following formula (3) or (4),
    Figure imgb0042
    wherein R⁵ a linear or branched alkyl group with 10 to 20 carbon atoms, X and X⁻ each
    individually represents a monoalkyl phosphate ion, a monoalkenyl phosphate ion, a monoalkyl phosphonate ion, or a monoalkenyl phosphonate ion having a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms.
  4. A composition for use in the oral cavity according to Claims 1-3, wherein said counter anion X⁻ is a phosphate ion represented by the following general formula (5),
    Figure imgb0043
    wherein R⁶ is a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms and R⁷ is a hydrogen atom, an alkali metal, an alkyl ammonium group, an alkyl ammonium group substituted by a hydroxy group, or a basic amino acid group residue.
  5. A composition for use in the oral cavity according to Claims 1-3, wherein said counter anion X⁻ is a phosphonate ion represented by the following general formula (6),
    Figure imgb0044
    wherein R⁸ is a linear or branched alkyl or alkenyl group with 8 to 20 carbon atoms and R⁹ is a hydrogen atom, an alkali metal, an alkyl ammonium group, an alkyl ammonium group substituted by a hydroxy group, or a basic amino acid group residue.
  6. A composition for use in the oral cavity according to Claim 1, further comprising,
    (C) a surfactant represented by the following general formula (7),
    Figure imgb0045
    wherein R¹⁰ is a linear or branched alkyl or alkenyl group with 8 to 30 carbon atoms, and Z¹ and Z² may be the same or different and each individually represents a hydrogen atom, an alkali metal, an alkyl ammonium group, an alkyl ammonium group substituted by a hydroxy group, or a basic amino acid group residue.
  7. A composition for use in the oral cavity comprising:
    (A') an antibacterial compound represented by the following general formula (8),
    Figure imgb0046
    wherein Am+ is a nitrogen-containing antibacterial cation and the counter anion Y⁻ represents a halogen ion or a gluconate ion, and m is a valence of the cation A,
    (B) a vehicle for use in the oral cavity, and
    (C) a surfactant represented by the following general formula (7),
    Figure imgb0047
    wherein R¹⁰ is a linear or branched alkyl or alkenyl group with 8 to 30 carbon atoms, and Z¹ and Z² may be the same or different and each individually represents a hydrogen atom, an alkali metal, an alkyl ammonium group, an alkyl ammonium group substituted by a hydroxy group, or a basic amino acid group residue; and
    wherein the molar amount of component (C) is m times or more of that of component (A').
  8. A composition for use in the oral cavity according to Claim 7, wherein said antibacterial compound (A') is a compound represented by the following formula (9),
    Figure imgb0048
    wherein at least one of R¹, R², or R³ is a linear or branched alkyl or alkenyl group with 8 to 30 carbon atoms, and others are individually a group selected from methyl group, ethyl group, benzyl group, and a group represented by one of the following formulas,
    Figure imgb0049
    -(CH₂CH₂O)n-H (wherein n is an integer of 1 to 15),
    Figure imgb0050
    or
    Figure imgb0051
    R⁴ represents a group -CH₃, -CH₂CH₃, or -CH₂CH₂OH; and the counter anion Y - 1
    Figure imgb0052
    represents a halogen ion.
  9. A composition for use in the oral cavity according to Claim 7, wherein said antibacterial compound (A') is a compound represented by the following formula (10) or (11),
    Figure imgb0053
    wherein R⁵ a linear or branched alkyl group with 10 to 20 carbon atoms, Y - 1
    Figure imgb0054
    is a halogen ion, and Y - 2
    Figure imgb0055
    represents a halogen ion or a gluconate ion.
  10. Use of a composition comprising compound (A) of Claim 1 for the preparation of a medicament to be used in oral cavity.
EP19930102227 1992-02-13 1993-02-12 Composition for use in oral cavity Expired - Lifetime EP0555864B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2674692 1992-02-13
JP26746/92 1992-02-13
JP12599892 1992-05-19
JP125998/92 1992-05-19

Publications (2)

Publication Number Publication Date
EP0555864A1 true true EP0555864A1 (en) 1993-08-18
EP0555864B1 EP0555864B1 (en) 1996-05-01

Family

ID=26364559

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19930102227 Expired - Lifetime EP0555864B1 (en) 1992-02-13 1993-02-12 Composition for use in oral cavity

Country Status (3)

Country Link
US (1) US5374418A (en)
EP (1) EP0555864B1 (en)
DE (2) DE69302413D1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569666A3 (en) * 1992-05-15 1994-10-12 Kao Corp Composition comprising a monophosphate for use in the oral cavity.
US5451401A (en) * 1993-09-29 1995-09-19 The Procter & Gamble Company Diphosphonic acid esters as tartar control agents
US5628986A (en) * 1994-11-18 1997-05-13 The Procter & Gamble Company Oral compositions
WO2003003832A1 (en) * 2001-07-06 2003-01-16 Rnl Life Science Ltd. Acid disinfectant composition comprising an anion surfactant
WO2010004361A2 (en) * 2008-06-17 2010-01-14 The Procter & Gamble Company Compositions and methods for improving overall tooth health and appearance
GB2533527A (en) * 2015-04-02 2016-06-22 Byotrol Plc Anti-microbial composition

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605676A (en) * 1995-06-26 1997-02-25 Colgate-Palmolive Company Oral composition exhibiting improved uptake and retention of antibacterial compounds on dental tissue surfaces
US5827503A (en) * 1996-08-08 1998-10-27 Collagenex Pharmaceuticals, Inc. Method and composition for treating periodontitis
US5800803A (en) * 1997-02-10 1998-09-01 Colgate-Palmolive Company Oral composition exhibiting enhanced uptake by dental tissue of noncationic antibacterial agents
US5939050A (en) * 1997-04-04 1999-08-17 Optiva Corp. Antimicrobial compositions
US6248309B1 (en) * 1997-04-04 2001-06-19 Optiva Corporation Gums containing antimicrobial agents
US6035634A (en) 1999-02-09 2000-03-14 Latch-Tool Development Co. Llc Compact, resistance regulated, multiple output hydraulic tool and seal valve arrangement
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
US20050048007A1 (en) * 2000-11-02 2005-03-03 Inobys Ltd. Plaque reducing composition
KR20050105230A (en) * 2003-02-21 2005-11-03 로디아 인코포레이티드 Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent
US9241885B2 (en) * 2004-01-29 2016-01-26 The Procter & Gamble Company Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials
US9242125B2 (en) * 2005-07-21 2016-01-26 Coglate-Palmolive Company Oral composition containing non-aggregated zinc nanoparticles
US8905760B2 (en) * 2008-11-04 2014-12-09 Duane C. Keller Methods and systems for progressively treating and controlling oral periopathogens causing systemic inflammations
US8956161B2 (en) 2008-11-04 2015-02-17 Duane C Keller Article and method for controlling oral-originated systemic disease
US8591229B2 (en) 2010-12-16 2013-11-26 Duane C. Keller Devices and methods for creating a positive pressure environment for treatment of oral biofilms associated with periodontal disease
WO2015041523A1 (en) 2013-09-18 2015-03-26 Glymur B.V. Oral hygiene compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192801A1 (en) * 1972-07-17 1974-02-15 Unilever Nv
DE2600708A1 (en) * 1975-01-15 1976-07-22 Colgate Palmolive Co Preparations for mouth and dental care
DE2744980A1 (en) * 1976-10-12 1978-04-13 Kao Corp Dentifrice
EP0150374A2 (en) * 1983-12-17 1985-08-07 Henkel Kommanditgesellschaft auf Aktien Mouth and tooth care compositions
EP0371542A2 (en) * 1988-12-01 1990-06-06 Unilever N.V. Oral composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864472A (en) * 1972-11-06 1975-02-04 Colgate Palmolive Co Clear lemon-flavored mouthwash
US4064138A (en) * 1975-11-12 1977-12-20 General Mills, Inc. Amino acid derivatives
US4256731A (en) * 1978-03-23 1981-03-17 Beecham, Inc. Oral Compositions
US4536519A (en) * 1981-06-15 1985-08-20 Kao Soap Co., Ltd. Emulsifying agent and emulsified cosmetics
US4391798A (en) * 1982-03-15 1983-07-05 Colgate-Palmolive Company Non-irritating dentifrice
US5128122A (en) * 1984-03-19 1992-07-07 The Rockefeller University Method and agents for preventing staining of teeth
US4670575A (en) * 1984-06-05 1987-06-02 Kao Corporation Process for purification of phosphoric mono esters
JPH0333376B2 (en) * 1986-05-06 1991-05-16 Kao Corp
JPS63225312A (en) * 1986-10-02 1988-09-20 Kao Corp Transparent or semitransparent jelly-like cosmetic
US5064640A (en) * 1986-12-02 1991-11-12 Purdue Research Foundation Anticariogenic compositions
US4997672A (en) * 1987-03-10 1991-03-05 Virginia Commonwealth University Salt taste enhancer
JPH0667818B2 (en) * 1988-06-20 1994-08-31 花王株式会社 Semi-transparent emulsified cosmetic
JPH0825861B2 (en) * 1989-04-24 1996-03-13 サンスター株式会社 Dentifrice composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192801A1 (en) * 1972-07-17 1974-02-15 Unilever Nv
DE2600708A1 (en) * 1975-01-15 1976-07-22 Colgate Palmolive Co Preparations for mouth and dental care
DE2744980A1 (en) * 1976-10-12 1978-04-13 Kao Corp Dentifrice
EP0150374A2 (en) * 1983-12-17 1985-08-07 Henkel Kommanditgesellschaft auf Aktien Mouth and tooth care compositions
EP0371542A2 (en) * 1988-12-01 1990-06-06 Unilever N.V. Oral composition

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569666A3 (en) * 1992-05-15 1994-10-12 Kao Corp Composition comprising a monophosphate for use in the oral cavity.
US5451401A (en) * 1993-09-29 1995-09-19 The Procter & Gamble Company Diphosphonic acid esters as tartar control agents
US5628986A (en) * 1994-11-18 1997-05-13 The Procter & Gamble Company Oral compositions
WO2003003832A1 (en) * 2001-07-06 2003-01-16 Rnl Life Science Ltd. Acid disinfectant composition comprising an anion surfactant
WO2010004361A2 (en) * 2008-06-17 2010-01-14 The Procter & Gamble Company Compositions and methods for improving overall tooth health and appearance
WO2010004361A3 (en) * 2008-06-17 2010-09-10 The Procter & Gamble Company Compositions and methods for improving overall tooth health and appearance
CN102056648B (en) * 2008-06-17 2014-11-05 宝洁公司 Compositions and methods for improving overall tooth health and appearance
GB2533527A (en) * 2015-04-02 2016-06-22 Byotrol Plc Anti-microbial composition
GB2533527B (en) * 2015-04-02 2018-10-17 Byotrol Plc Anti-microbial composition

Also Published As

Publication number Publication date Type
US5374418A (en) 1994-12-20 grant
DE69302413D1 (en) 1996-06-05 grant
EP0555864B1 (en) 1996-05-01 grant
DE69302413T2 (en) 1996-10-17 grant

Similar Documents

Publication Publication Date Title
US5281410A (en) Methods of reducing plaque and gingivitis with reduced staining
US4490353A (en) Antiplaque dentifrice with improved fluoride stability
US4041149A (en) Composition and method of controlling and preventing mouth odor
US5000944A (en) Zinc-containing oral products with reduced astringency
US4522806A (en) Oral compositions for hexetidine and zinc salts for the synergistic inhibition of dental plaque
US5605676A (en) Oral composition exhibiting improved uptake and retention of antibacterial compounds on dental tissue surfaces
US4839156A (en) Stable hydrogen peroxide dental gel
US4183914A (en) Magnesium polycarboxylate complexes and anticalculus agents
US4846650A (en) Oral compositions and methods for reducing dental calculus
US5451401A (en) Diphosphonic acid esters as tartar control agents
US4469674A (en) Stable oral compositions containing zinc and fluoride compounds
US5015467A (en) Combined anticalculus and antiplaque compositions
US5147632A (en) Anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent
US5681548A (en) Oral formulations
US5538714A (en) Use of polyvinyl pyrrolidone for reducing the adherence of oral bacteria
US3937805A (en) Method of making dentifrice compositions containing insolubilized salts of 1,6-di-(p-chlorophenyl biguanido) hexane
US5116602A (en) Antiplaque oral compositions
US5032385A (en) Oral hygiene composition
US5891422A (en) Antimicrobial composition containing a C3 -C6 alcohol
US4137303A (en) Antibacterial oral composition
US20040185027A1 (en) Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent
US5578295A (en) Oral care compositions comprising certain substituted diphenyl ethers
US4138477A (en) Composition to control mouth odor
US5188820A (en) Method of inhibiting plaque on teeth by applying an oral composition
US4272512A (en) Antigingivitis composition

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): DE FR GB

RIN1 Inventor (correction)

Inventor name: IWASAKI, TETSUJI

Inventor name: EGUCHI, YASUTERU

Inventor name: YAMAGISHI, ATSUSHI

Inventor name: HIOKI, YUICHI

Inventor name: NAKAI, RYOZO

Inventor name: OSHINO, KAZUHI

17P Request for examination filed

Effective date: 19931123

17Q First examination report

Effective date: 19950123

AK Designated contracting states:

Kind code of ref document: B1

Designated state(s): DE FR GB

REF Corresponds to:

Ref document number: 69302413

Country of ref document: DE

Date of ref document: 19960605

ET Fr: translation filed
26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Postgrant: annual fees paid to national office

Ref country code: GB

Payment date: 20070207

Year of fee payment: 15

PGFP Postgrant: annual fees paid to national office

Ref country code: DE

Payment date: 20070208

Year of fee payment: 15

PGFP Postgrant: annual fees paid to national office

Ref country code: FR

Payment date: 20070208

Year of fee payment: 15

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080212

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20081031

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080902

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080229

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080212